Therapeutic potential of new 4-hydroxy-tamoxifen-loaded pH-gradient liposomes in a multiple myeloma experimental model

Pharmaceutical Research

Volumn 27, Issue 2, 2010, Pages 327-339

  Urbinati, Giorgia ^a,b,c   Audisio, Davide ^a,b,c   Marsaud, Véronique ^a,b,c   Plassat, Vincent ^a,b,c   Arpicco, Silvia ^d   Sola, Brigitte ^e   Fattal, Elias ^a,b,c   Renoir, Jack Michel ^a,b,c  

^a CNRS   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c IPSIT   (France)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITÉ DE CAEN   (France)

Author keywords

Breast cancer; Hydroxy tamoxifen; Multiple myeloma; PH gradient Stealth liposomes

Indexed keywords

4 HYDROXYTAMOXIFEN; CASPASE 3; CD34 ANTIGEN; DIPALMITOYLPHOSPHATIDYLCHOLINE CHOLESTEROL DISTEAROYLPHOSPHOETHANOLAMINE POLY (ETHYLENE) GLYCOL LIPOSOME; KI 67 ANTIGEN; LIPOSOME; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KINETICS; LIPID COMPOSITION; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PH MEASUREMENT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; TUMOR CELL; TUMOR VASCULARIZATION;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LIPOSOMES; MICE; MICE, NUDE; MULTIPLE MYELOMA; PROTON-MOTIVE FORCE; TAMOXIFEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77949268976     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-009-0023-z     Document Type: Article

References (73)

1. B Fisher JP Costantino DL Wickerham CK Redmond M Kavanah WM Cronin, et al. 1998 Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study J Natl Cancer Inst. 90 1371 88 10.1093/jnci/90.18.1371 1:CAS:528:DyaK1cXmtlelurs%3D 9747868
2. VC Jordan VC Jordan 2006 Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer Br J Pharmacol. 147 Suppl 1 S269 76 10.1038/sj.bjp.0706399 1:CAS:528:DC%2BD28XisVCnsA%3D%3D 16402113 (Pubitemid 43077285)
3. CA Ellis MD Vos M Wickline C Riley T Vallecorsa WG Telford, et al. 2003 Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines Breast Cancer Res Treat. 78 59 67 10.1023/A:1022105511409 1:CAS:528:DC%2BD3sXntV2rtQ%3D%3D 12611458 (Pubitemid 36223018)
4. M Obrero DV Yu DJ Shapiro 2002 Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death J Biol Chem. 277 45695 703 10.1074/jbc.M208092200 1:CAS:528:DC%2BD38Xosl2kt7c%3D 12244117 (Pubitemid 36159182)
5. A Zheng A Kallio P Harkonen 2007 Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen Endocrinology 148 2764 77 10.1210/en.2006-1269 1:CAS:528:DC%2BD2sXmt1ajtL0%3D 17363451 (Pubitemid 46984781)
6. M Dutertreand CL Smith 2000 Molecular mechanisms of selective estrogen receptor modulator (SERM) action J Pharmacol Exp Ther. 295 431 7
7. JI MacGregor VC Jordan 1998 Basic guide to the mechanisms of antiestrogen action Pharmacol Rev. 50 151 96 1:CAS:528:DyaK1cXksFClsbY%3D 9647865
8. DJ Mangelsdorf C Thummel M Beato P Herrlich G Schutz K Umesono, et al. 1995 The nuclear receptor superfamily: the second decade Cell 83 835 9 10.1016/0092-8674(95)90199-X 1:CAS:528:DyaK2MXhtVSnu7nJ 8521507 (Pubitemid 26006525)
9. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717.
10. JE Rossouw GL Anderson RL Prentice AZ LaCroix C Kooperberg ML Stefanick, et al. 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial JAMA 288 321 33 10.1001/jama.288.3.321 1:CAS:528:DC%2BD38Xltlegs7k%3D 12117397
11. GJ Goldenberg EK Froese 1982 Drug and hormone sensitivity of estrogen receptor-positive and -negative human breast cancer cells in vitro Cancer Res. 42 5147 51 1:CAS:528:DyaL3sXivVSrtg%3D%3D 7139616
12. EP Gelmann 1997 Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma Semin Oncol. 24 S1-65 S1-70
13. de Medina P, Payre B, Boubekeur N, Bertrand-Michel J, Terce F, Silvente-Poirot S, et al. Ligands of the antiestrogen-binding site induce active cell death and autophagy in human breast cancer cells through the modulation of cholesterol metabolism. Cell Death Differ. 2009.
14. NN Sjak-Shie RA Vescio JR Berenson 2000 Recent advances in multiple myeloma Curr Opin Hematol. 7 241 6 10.1097/00062752-200007000-00007 1:STN:280:DC%2BD3M%2FjtVGlsg%3D%3D 10882180 (Pubitemid 30387848)
15. SP Treon G Teoh M Urashima A Ogata D Chauhan IJ Webb, et al. 1998 Anti-estrogens induce apoptosis of multiple myeloma cells Blood 92 1749 57 1:CAS:528:DyaK1cXls1Shs7s%3D 9716605
16. T Otsuki O Yamada J Kurebayashi T Moriya H Sakaguchi H Kunisue, et al. 2001 Estrogen receptors in human myeloma cells Cancer Res. 60 1434 41
17. J Gauduchon F Gouilleux S Maillard V Marsaud JM Renoir B Sola 2005 The 4-hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro and in vivo through down-regulation of c-Myc, up-regulation of p27Kip1 and modulation of Bcl-2 family members Clin Cancer Res. 11 2345 54 10.1158/1078-0432.CCR-04-1668 1:CAS:528:DC%2BD2MXisFaisr0%3D 15788686 (Pubitemid 40490196)
18. J Gauduchon A Seguin V Marsaud D Clay JM Renoir B Sola 2008 Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspases Int J Cancer. 122 2130 41 10.1002/ijc.23310 1:CAS:528:DC%2BD1cXkt1Chsbk%3D 18183592
19. B Sola JM Renoir 2007 Estrogenic or antiestrogenic therapies for multiple myeloma? Mol Cancer 6 59 10.1186/1476-4598-6-59 17888187 (Pubitemid 350176268)
20. S Olivier P Close E Castermans L de Leval S Tabruyn A Chariot, et al. 2006 Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-kappaB inhibition and gene expression signature Mol Pharmacol. 69 1615 23 10.1124/mol.105.020479 1:CAS:528:DC%2BD28XksVWrt7c%3D 16497877
21. OW Prall EM Rogan RL Sutherland 1998 Estrogen regulation of cell cycle progression in breast cancer cells J Steroid Biochem Mol Biol. 65 169 74 10.1016/S0960-0760(98)00021-1 1:CAS:528:DyaK1cXkvVKru7Y%3D 9699870 (Pubitemid 28335603)
22. R Clarke F Leonessa JN Welch TC Skaar 2001 Cellular and molecular pharmacology of antiestrogen action and resistance Pharmacol Rev. 53 25 71 1:CAS:528:DC%2BD3MXhsFWqtLY%3D 11171938 (Pubitemid 32173107)
23. H Rochefort JL Borgna 1981 Differences between oestrogen receptor activation by oestrogen and antioestrogen Nature 292 257 9 10.1038/292257a0 1:CAS:528:DyaL3MXmtFGns7w%3D 7254318 (Pubitemid 11001845)
24. BS Katzenellenbogen MM Montano P Le Goff DJ Schodin WL Kraus B Bhardwaj, et al. 1995 Antiestrogens: mechanisms and actions in target cells J Steroid Biochem Mol Biol. 53 387 93 10.1016/0960-0760(95)00084-D 1:CAS:528: DyaK2MXnt1GntLo%3D 7626486
25. I Brigger P Chaminade V Marsaud M Appel M Besnard R Gurny, et al. 2001 Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation Int J Pharm. 214 37 42 10.1016/S0378-5173(00)00628-1 1:CAS:528:DC%2BD3MXitFWgs7k%3D 11282234 (Pubitemid 32244075)
26. JS Chawla MM Amiji 2002 Biodegradable poly(epsilon -caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen Int J Pharm. 249 127 38 10.1016/S0378-5173(02)00483-0 1:CAS:528:DC%2BD38XosFagu74%3D 12433441 (Pubitemid 35333439)
27. H Devalapally Z Duan MV Seiden MM Amiji 2008 Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles Clin Cancer Res. 14 3193 203 10.1158/1078-0432.CCR-07-4973 1:CAS:528:DC%2BD1cXmtVCmu74%3D 18483388
28. D Shenoy S Little R Langer M Amiji 2005 Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies Pharm Res. 22 2107 14 10.1007/s11095-005-8343-0 1:CAS:528:DC%2BD2MXhtlemtbbM 16254763 (Pubitemid 41821590)
29. E Memisoglu-Bilensoy I Vural A Bochot JM Renoir D Duchene AA Hincal 2005 Tamoxifen citrate loaded amphiphilic beta-cyclodextrin nanoparticles: in vitro characterization and cytotoxicity J Control Release 104 489 96 1:CAS:528:DC%2BD2MXksVyjtbk%3D 15911048
30. FX Hu KG Neoh ET Kang 2006 Synthesis and in vitro anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA composite nanoparticles Biomaterials 27 5725 33 10.1016/j.biomaterials.2006.07.014 1:CAS:528:DC%2BD28Xos12qtbo%3D 16890989 (Pubitemid 44294822)
31. JM Renoir B Stella T Ameller E Connault P Opolon V Marsaud 2006 Improved anti-tumoral capacity of mixed and pure anti-oestrogens in breast cancer cell xenografts after their administration by entrapment in colloidal nanosystems J Steroid Biochem Mol Biol. 102 114 27 10.1016/j.jsbmb.2006.09.001 1:CAS:528:DC%2BD28Xht1Cmt7bP 17056251 (Pubitemid 44781183)
32. T Ameller V Marsaud P Legrand R Gref G Barratt JM Renoir 2003 Polyester-poly(ethylene glycol) nanoparticles loaded with the pure antiestrogen RU 58668: physicochemical and opsonization properties Pharm Res. 20 1063 70 10.1023/A:1024418524688 1:CAS:528:DC%2BD3sXkvFSlu7c%3D 12880293 (Pubitemid 36774278)
33. S Maillard J Gauduchon V Marsaud F Gouilleux E Connault P Opolon, et al. 2006 Improved antitumoral properties of pure antiestrogen RU 58668-loaded liposomes in multiple myeloma J Steroid Biochem Mol Biol. 100 67 78 10.1016/j.jsbmb.2006.03.008 1:CAS:528:DC%2BD28Xntl2msr8%3D 16753295 (Pubitemid 44088614)
34. A Bhatia R Kumar OP Katare 2004 Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation J Pharm Pharm Sci. 7 252 9 1:CAS:528:DC%2BD2cXnt1Slsro%3D 15367383
35. R Zeisig AD Teppke D Behrens I Fichtner 2004 Liposomal 4-hydroxy-tamoxifen: effect on cellular uptake and resulting cytotoxicity in drug resistant breast cancer cells in vitro Breast Cancer Res Treat. 87 245 54 10.1007/s10549-004-8699-6 1:CAS:528:DC%2BD2cXptlSlu70%3D 15528967 (Pubitemid 39505941)
36. R Zeisig D Ruckerl I Fichtner 2004 Reduction of tamoxifen resistance in human breast carcinomas by tamoxifen-containing liposomes in vivo Anticancer Drugs 15 707 14 10.1097/01.cad.0000136885.65293.e9 1:CAS:528: DC%2BD2cXlvValuro%3D 15269602 (Pubitemid 39099920)
37. Daoud-Mahammed S, Couvreur P, Bouchemal K, Cheron M, Lebas G, Amiel C, et al. Cyclodextrin and Polysaccharide-Based Nanogels: Entrapment of Two Hydrophobic Molecules, Benzophenone and Tamoxifen. Biomacromolecules 2009.
38. DD Lasic PM Frederik MC Stuart Y Barenholz TJ McIntosh 1992 Gelation of liposome interior. A novel method for drug encapsulation FEBS Lett. 312 255 8 10.1016/0014-5793(92)80947-F 1:CAS:528:DyaK3sXhtFKltw%3D%3D 1426260
39. G Haran R Cohen LK Bar Y Barenholz 1993 Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases Biochim Biophys Acta. 1151 201 15 10.1016/0005-2736(93)90105-9 1:CAS:528:DyaK2cXjsl2huw%3D%3D 8373796 (Pubitemid 23283973)
40. PR Harrigan KF Wong TE Redelmeier JJ Wheeler PR Cullis 1993 Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients Biochim Biophys Acta. 1149 329 38 10.1016/0005-2736(93)90218-O 1:CAS:528:DyaK3sXlsVKnu7Y%3D 8323951 (Pubitemid 23197692)
41. M Celano MG Calvagno S Bulotta D Paolino F Arturi D Rotiroti, et al. 2004 Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells BMC Cancer 4 63 10.1186/1471-2407-4-63 15363094
42. B Stella S Arpicco F Rocco V Marsaud JM Renoir L Cattel, et al. 2007 Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules Int J Pharm. 344 71 7 10.1016/j.ijpharm.2007.06.006 1:CAS:528:DC%2BD2sXhtV2qtb%2FK 17651931 (Pubitemid 47464827)
43. SA Abraham K Edwards G Karlsson N Hudon LD Mayer MB Bally 2004 An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes J Control Release 96 449 61 10.1016/j.jconrel.2004.02.017 1:CAS:528:DC%2BD2cXjsFOltL0%3D 15120901 (Pubitemid 38553923)
44. SA Abraham C McKenzie D Masin R Ng TO Harasym LD Mayer, et al. 2004 In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading Clin Cancer Res. 10 728 38 10.1158/1078-0432.CCR-1131-03 1:CAS:528:DC%2BD2cXovVKjuw%3D%3D 14760096 (Pubitemid 38174011)
45. C Chemin JM Pean C Bourgaux G Pabst P Wuthrich P Couvreur, et al. 2009 Supramolecular organization of S12363-liposomes prepared with two different remote loading processes Biochim Biophys Acta 1788 926 35 10.1016/j.bbamem.2008. 11.017 1:CAS:528:DC%2BD1MXltVyqtr0%3D 19101501
46. E Ramsay J Alnajim M Anantha J Zastre H Yan M Webb, et al. 2008 A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention Eur J Pharm Biopharm. 68 607 17 10.1016/j.ejpb.2007.08.011 1:CAS:528:DC%2BD1cXjtVeksbg%3D 17904831 (Pubitemid 351318211)
47. M Pons D Gagne JC Nicolas M Mehtali 1990 A new cellular model of response to estrogens: a bioluminescent test to characterize (anti) estrogen molecules Biotechniques 9 450 9 1:CAS:528:DyaK3MXksVais78%3D 2257144
48. P Balaguer F Francois F Comunale H Fenet AM Boussioux M Pons, et al. 1999 Reporter cell lines to study the estrogenic effects of xenoestrogens Sci Total Environ. 233 47 56 10.1016/S0048-9697(99)00178-3 1:CAS:528:DyaK1MXltlClu7c%3D 10492897 (Pubitemid 29389755)
49. S Maillard T Ameller J Gauduchon A Gougelet F Gouilleux P Legrand, et al. 2005 Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma J Steroid Biochem Mol Biol. 94 111 21 10.1016/j.jsbmb.2004.12.023 1:CAS:528:DC%2BD2MXjvVKksrY%3D 15862956 (Pubitemid 40614524)
50. V Marsaud A Gougelet S Maillard JM Renoir 2003 Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells Mol Endocrinol. 17 2013 27 10.1210/me.2002-0269 1:CAS:528:DC%2BD3sXotFSrsLc%3D 12855746 (Pubitemid 37281794)
51. SM Moghimi J Szebeni 2003 Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties Prog Lipid Res. 42 463 78 10.1016/S0163-7827(03) 00033-X 1:CAS:528:DC%2BD3sXotVequ7o%3D 14559067 (Pubitemid 37237636)
52. TM Allen PR Cullis 2004 Drug delivery systems: entering the mainstream Science 303 1818 22 10.1126/science.1095833 1:CAS:528:DC%2BD2cXitFehu70%3D 15031496 (Pubitemid 38374867)
53. CK Watts A Brady B Sarcevic A deFazio EA Musgrove RL Sutherland 1995 Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation Mol Endocrinol. 9 1804 13 10.1210/me.9.12.1804 1:CAS:528:DyaK2MXhtVSjtLvE 8614416
54. S Cariou JC Donovan WM Flanagan A Milic N Bhattacharya JM Slingerland 2000 Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells Proc Natl Acad Sci USA. 97 9042 6 10.1073/pnas.160016897 1:CAS:528:DC%2BD3cXls12lu7c%3D 10908655 (Pubitemid 30626670)
55. T Otsuki O Yamada J Kurebayashi T Moriya H Sakaguchi H Kunisue, et al. 2000 Estrogen receptors in human myeloma cells Cancer Res. 60 1434 41 1:CAS:528:DC%2BD3cXhvFWrtLc%3D 10728710
56. E Berman M Adams R Duigou-Osterndorf L Godfrey B Clarkson M Andreeff 1991 Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype Blood 77 818 25 1:CAS:528:DyaK3MXhslOqtbo%3D 1993221
57. DL Trump DC Smith PG Ellis MP Rogers SC Schold EP Winer, et al. 1992 High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine J Natl Cancer Inst. 84 1811 6 10.1093/jnci/84.23.1811 1:STN:280:DyaK3s%2FlvFCktg%3D%3D 1359155
58. M Demoy S Gibaud JP Andreux C Weingarten B Gouritin P Couvreur 1997 Splenic trapping of nanoparticles: complementary approaches for in situ studies Pharm Res. 14 463 8 10.1023/A:1012095431931 1:CAS:528:DyaK2sXjtVWrsb8%3D 9144732 (Pubitemid 27205005)
59. CK Osborne 1998 Tamoxifen in the treatment of breast cancer N Engl J Med. 339 1609 18 10.1056/NEJM199811263392207 1:CAS:528:DyaK1cXnvFOitLs%3D 9828250 (Pubitemid 28536137)
60. Bhatia A, Bhushan S, Singh B, Katare OP. Studies on Tamoxifen Encapsulated in Lipid Vesicles: Effect on the Growth of Human Breast Cancer MCF-7 Cells. J Liposome Res. 2008;1-6.
61. H Wiseman P Quinn B Halliwell 1993 Tamoxifen and related compounds decrease membrane fluidity in liposomes. Mechanism for the antioxidant action of tamoxifen and relevance to its anticancer and cardioprotective actions? FEBS Lett. 330 53 6 10.1016/0014-5793(93)80918-K 1:CAS:528:DyaK3sXlvFGhtL4%3D 8370459 (Pubitemid 23263040)
62. D Chauhan L Catley T Hideshima G Li R Leblanc D Gupta, et al. 2002 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells Blood 100 2187 94 10.1182/blood-2002-02-0376 1:CAS:528:DC%2BD38Xnt1yhsLc%3D 12200384 (Pubitemid 35001255)
63. M Cuendet K Christov DD Lantvit Y Deng S Hedayat L Helson, et al. 2004 Multiple myeloma regression mediated by bruceantin Clin Cancer Res. 10 1170 9 10.1158/1078-0432.CCR-0362-3 1:CAS:528:DC%2BD2cXhtFCnsrs%3D 14871997 (Pubitemid 38198919)
64. T Hideshima KC Anderson 2002 Molecular mechanisms of novel therapeutic approaches for multiple myeloma Nat Rev Cancer 2 927 37 10.1038/nrc952 1:CAS:528:DC%2BD38XptFCjsb0%3D 12459731 (Pubitemid 37328894)
65. S Garvin C Dabrosin 2003 Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo Cancer Res. 63 8742 8 1:CAS:528:DC%2BD3sXhtVSqtb7P 14695189
66. Bouclier C, Marsaud V, Bawa O, Nicolas V, Moine L, Opolon P, et al. Coadministration of nanosystems of short silencing RNAs targeting oestrogen receptor alpha and anti-oestrogen synergistically induces tumour growth inhibition in human breast cancer xenografts. Breast Cancer Res Treat 2009.
67. K Podar KC Anderson 2005 The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications Blood 105 1383 95 10.1182/blood-2004-07- 2909 1:CAS:528:DC%2BD2MXhsVChtrc%3D 15471951 (Pubitemid 40223651)
68. B Barlogie J Shaughnessy G Tricot J Jacobson M Zangari E Anaissie, et al. 2004 Treatment of multiple myeloma Blood 103 20 32 10.1182/blood-2003-04-1045 1:CAS:528:DC%2BD2cXhsFCrtQ%3D%3D 12969978 (Pubitemid 38029914)
69. EA Obeng LM Carlson DM Gutman WJ Harrington Jr KP Lee LH Boise 2006 Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells Blood 107 4907 16 10.1182/blood-2005-08-3531 1:CAS:528: DC%2BD28XlvFCgtL8%3D 16507771 (Pubitemid 43882644)
70. A Fribley CY Wang 2006 Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress Cancer Biol Ther. 5 745 8 1:CAS:528:DC%2BD28XhtVOju77J 16861900
71. SF Doisneau-Sixou CM Sergio JS Carroll R Hui EA Musgrove RL Sutherland 2003 Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells Endocr Relat Cancer 10 179 86 10.1677/erc.0.0100179 1:CAS:528:DC%2BD3sXmsFCrsr0%3D 12790780 (Pubitemid 36758647)
72. CE Caldon RJ Daly RL Sutherland EA Musgrove 2006 Cell cycle control in breast cancer cells J Cell Biochem. 97 261 74 10.1002/jcb.20690 1:CAS:528:DC%2BD28XhvFyhurg%3D 16267837 (Pubitemid 43167144)
73. W Bursch A Ellinger H Kienzl L Torok S Pandey M Sikorska, et al. 1996 Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy Carcinogenesis 17 1595 607 10.1093/carcin/17.8.1595 1:CAS:528:DyaK28XlsVegsLk%3D 8761415